



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O'Brien et al.

§ ART UNIT:  
§ 1642

FILED: October 20, 1999

§ EXAMINER:  
§ Harris, A.

SERIAL NO.: 09/421,213

§ DOCKET:  
§ D6064CIP

FOR: TADG-15: An Extracellular Serine  
Protease Overexpressed In Carcinomas

#  
24/F  
KD  
9-13

The Honorable Commissioner of Patents  
BOX NON-FEE AMENDMENT  
Washington, DC 20231

RESPONSE UNDER 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action mailed April 3, 2002, please enter the following amendments and remarks. Reconsideration of the pending claims is respectfully requested.

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

AMENDMENTS

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 9, line 19, with the following rewritten paragraph:

Figures 1A and 1B show a comparison of the serine protease catalytic domain of TADG-15 with Hepsin (Heps, SEQ ID No. 3), SCCE (SEQ ID No. 4), Trypsin, (Try, SEQ ID No. 5), Chymotrypsin (Chymb,